Amneal Pharmaceuticals Inc (AMRX) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Amneal Pharmaceuticals Inc   (NASDAQ: AMRX)

Amneal Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Amneal Pharmaceuticals Inc in the second quarter 2026?
Due to the lack of equity, it was not possible to calculate Amneal Pharmaceuticals Inc 's return on equity (ROE) in its second quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change 95.49 % 216.84 % - 54.22 % 112.13 %
Net Income (TTM) in Millions 215 181 128 58 51
Return On Equity (TTM) - - - - -
AMRX's Total Ranking # # # # #
Equity (TTM) in Millions 33 -46 -71 -110 -113
Seq. Equity Change - - - - -
Seq. Net Income Change -10.75 % 57.34 % 173.4 % -49.08 % 44.65 %

Back to AMRX Management Effectiveness >> AMRX's 5 Years Annual ROE >> Compare AMRX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





AMRX Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions -71 -110 20 184 367
Y / Y Equity Change - - -89.12 % -49.87 % 6.39 %
Net Income in Millions 128 -74 -49 -255 20
Y / Y Net Income Change - - - - -70.59 %
Return On Equity - - -243.48 % -138.49 % 5.5 %

Back to AMRX Management Effectiveness >> AMRX's 5 Years Annual ROE >> Compare AMRX ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 5.5 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AMRX's' Return on Equity at Yahoo Finance
AMRX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AMRX's Competitors
Subscribers only: Roe for Amneal Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for AMRX's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-08T16:31:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.